Latest - Page 2 of 4 - Rivervest - News & Press / Case Studies / Articles

News & Press

RiverVest Builds Another San Diego Based Biopharma Company

News & Press

Sivan Weitzman Joins RiverVest Venture Partners as CFO

News & Press

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

News & Press

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

News & Press

RiverVest Venture Partners Expands Scientific Advisory Board

News & Press

St. Louis Venture Fund Makes $15 Million Bet on its Hometown

Reneo Pharmaceuticals Announces Pricing of Initial Public Offering – 4/8/2021
OncoResponse Raises $40.6 Million in Series C Financing – 3/31/2021
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting – 3/30/2021
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives – 3/29/2021
Mirum Pharmaceuticals Announces FDA Acceptance of the New Drug Application and Priority Review for Maralixibat in Alagille Syndrome – 3/29/2021
Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting – 3/17/2021
Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors – 3/15/2021
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021 – 3/10/2021
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – 3/10/2021
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates – 3/9/2021
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia for Cell Therapies to Treat Cancer – 3/8/2021
Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting – 3/2/2021
Wugen Announces Exclusive License Agreement with HCW Biologics for Cell Therapies to Treat Cancer – 3/2/2021
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update – 3/1/2021
Wugen Announces the Appointment of Company’s Co-founder Matt Cooper, Ph.D., as Chief Scientific Officer – 3/1/2021
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline – 2/24/2021
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-178 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors – 2/9/2021
Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis – 2/22/2021
Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome – 2/1/2021
VentureMed’s FLEX Vessel Prep™ System Data Presented During Leipzig Interventional Course (LINC) 2021 – 1/27/2021
Cardialen Awarded $2.8 Million Federal Grant to Advance Therapy Designed to Treat Dangerous Heart Rhythms – 1/19/2021
Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis – 1/14/2021
Mirum Pharmaceuticals Provides Corporate Update – 01/12/2021
Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain – 1/7/2021
Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock – 12/14/2020
Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement – 12/09/2020
Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth – 12/09/2020
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma — 12/07/2020
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2 – 11/30/2020
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC – 11/12/2020
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting – 11/2/2020
Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) – 11/2/2020
Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes – 10/28/2020
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002) – 10/26/2020
Results from Allakos’s Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed – 10/26/2020
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine – 10/21/2020